Description: A prospective, international multi-center, randomized, double-blind, placebo-controlled study of Natrecor® in patients with NYHA Class IV Congestive Heart Failure (or Class III with renal impairment) who are on maximal oral medications and who continue to have recurrent hospital admissions for decompensated CHF. Principal Investigator: Shelley Hall, M.D. Location: Heartplace Baylor Primary Objective: To evaluate the efficacy and safety of Natrecor® administered as serial infusions to heart failure (HF) patients in the outpatient setting. Contact Information: Cory White (214.820.7825)
